Phio Pharmaceuticals Corp. (PHIO) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
257 SIMARANO DRIVE MARLBOROUGH, MA 01752 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 24,057 | 14,244 | 6,934 | 14,879 | 3,581 | 12,906 | 10,617 | ||
| Cash and cash equivalents | 24,057 | 14,244 | 6,934 | 14,879 | 3,581 | 12,906 | 5,117 | ||
| Short-term investments | 5,500 | ||||||||
| Restricted cash and investments | 50 | ||||||||
| Prepaid expense | 150 | 311 | |||||||
| Other undisclosed current assets | 670 | 920 | 366 | 271 | 201 | 50 | 50 | ||
| Total current assets: | 24,727 | 15,164 | 7,300 | 15,150 | 3,832 | 13,106 | 10,978 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 283 | 400 | 511 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 133 | 157 | 210 | 172 | 248 | 114 | 163 | ||
| Long-term investments and receivables | 150 | ||||||||
| Accounts and financing receivable, after allowance for credit loss | 150 | ||||||||
| Other noncurrent assets | 27 | 18 | 18 | 18 | 27 | 18 | |||
| Total noncurrent assets: | 443 | 575 | 739 | 172 | 266 | 291 | 181 | ||
| TOTAL ASSETS: | 25,170 | 15,739 | 8,039 | 15,322 | 4,098 | 13,397 | 11,159 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,943 | 2,080 | 1,773 | 1,744 | 2,265 | 2,542 | 2,269 | ||
| Accounts payable | 283 | 728 | 809 | 550 | 511 | 917 | 1,163 | ||
| Accrued liabilities | 2,660 | 1,352 | 964 | 1,194 | 1,754 | 1,625 | 1,106 | ||
| Debt | 107 | ||||||||
| Other undisclosed current liabilities | 125 | 116 | |||||||
| Total current liabilities: | 3,068 | 2,196 | 1,880 | 1,744 | 2,265 | 2,542 | 2,269 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 170 | 526 | 411 | ||||||
| Long-term debt, excluding current maturities | 231 | ||||||||
| Operating lease, liability | 170 | 295 | 411 | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | (170) | (295) | |||||||
| Total noncurrent liabilities: | 170 | 526 | 411 | ||||||
| Total liabilities: | 3,238 | 2,722 | 2,291 | 1,744 | 2,265 | 2,542 | 2,269 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 21,932 | 13,017 | 5,748 | 13,578 | 1,833 | 10,855 | 8,890 | ||
| Common stock | 1 | 1 | 1 | 2 | 1 | 7 | |||
| Additional paid in capital | 138,831 | 116,629 | 100,566 | 99,487 | 80,384 | 73,428 | 65,988 | ||
| Accumulated deficit | (116,900) | (103,613) | (94,819) | (85,911) | (78,551) | (66,099) | (57,105) | ||
| Other undisclosed stockholders' equity attributable to parent | 3,525 | ||||||||
| Total stockholders' equity: | 21,932 | 13,017 | 5,748 | 13,578 | 1,833 | 10,855 | 8,890 | ||
| TOTAL LIABILITIES AND EQUITY: | 25,170 | 15,739 | 8,039 | 15,322 | 4,098 | 13,397 | 11,159 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 21 | 138 | 15 | 19 | 34 | |||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 34 | |||
| Gross profit: | 21 | 138 | 15 | 19 | 34 | |||
| Operating expenses | (13,511) | (8,793) | (9,008) | (7,502) | (14,077) | (9,034) | (10,271) | |
| Operating loss: | (13,511) | (8,793) | (8,987) | (7,364) | (14,062) | (9,015) | (10,237) | |
| Nonoperating income (expense) | 224 | (1) | 79 | 4 | (11) | 21 | 14 | |
| Other nonoperating income (expense) | (10) | 6 | (2) | |||||
| Interest and debt expense | 233 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (13,054) | (8,794) | (8,908) | (7,360) | (14,073) | (8,994) | (10,223) | |
| Other undisclosed loss from continuing operations before income taxes | (233) | |||||||
| Loss from continuing operations before income taxes: | (13,287) | (8,794) | (8,908) | (7,360) | (14,073) | (8,994) | (10,223) | |
| Income tax benefit | 2,641 | 2,532 | 2,194 | 1,621 | 3,633 | 3,960 | ||
| Net loss: | (13,287) | (6,153) | (6,376) | (5,166) | (12,452) | (5,361) | (6,263) | |
| Other undisclosed net loss attributable to parent | (2,641) | (2,532) | (2,194) | (3,633) | (3,960) | |||
| Net loss attributable to parent: | (13,287) | (8,794) | (8,908) | (7,360) | (12,452) | (8,994) | (10,223) | |
| Preferred stock dividends and other adjustments | (2,075) | (209) | ||||||
| Net loss available to common stockholders, diluted: | (13,287) | (8,794) | (8,908) | (7,360) | (12,452) | (11,069) | (10,432) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (13,287) | (6,153) | (6,376) | (5,166) | (12,452) | (5,361) | (6,263) | |
| Comprehensive loss, net of tax, attributable to parent: | (13,287) | (6,153) | (6,376) | (5,166) | (12,452) | (5,361) | (6,263) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.